In December our Patient Advocacy team attended the American Society of Hematology (ASH) 2019 meeting in Florida, along with our trustee Dr Manos Nikolousis.
In this video, he describes how, thanks to increasing use of genetic and molecular information, newer non-chemotherapy medicines are changing the treatment of acute myeloid leukaemia (AML). youtu.be/dEQyvbOqISE